Actively Recruiting
Phase 1 Study of BEAM-201, an Allogeneic Anti-CD7 CAR-T Cell Therapy, for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Patients Up to 29 Years
Led by Stephan Grupp MD PhD · Updated on 2026-07-07
33
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effectiveness of an investigational treatment called BEAM-201 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia T-ALL or T-cell lymphoblastic lymphoma T-LLy. These conditions have poor outcomes after relapse, with low survival rates and limited options beyond stem cell transplant. BEAM-201 is an allogeneic anti-CD7 CAR T cell therapy showing early promising results, especially since most T-ALL cases express the CD7 protein targeted by this therapy. The study includes a dose escalation phase using a standard 33 design to find the maximum tolerated dose of BEAM-201, with three planned dose levels and a possible dose de-escalation. If a lower dose shows sufficient response, further escalation may be skipped. After establishing safety at a dose level, a dose expansion phase will open to enroll more patients. BEAM-201 is prepared by editing donor T cells to express an anti-CD7 chimeric antigen receptor. Participants will be monitored for safety and response over up to five years, including assessments of adverse events, remission status, minimal residual disease, eligibility for stem cell transplant, duration of response, and overall survival. The study involves regular medical evaluations, laboratory tests, and follow-up visits to track treatment effects and patient health. This long-term monitoring aims to understand the treatments impact and guide future care options.
CONDITIONS
Brief Title
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Research Team
C
Cell Therapy Intake Team
M
Melissa S Varghese, M.S.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here